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Effect of Triamcinolone Acetonide Injections on
Hemiplegic Shoulder Pain
A Randomized Clinical Trial
Ingrid A.K. Snels, MD; Heleen Beckerman, PT, PhD; Jos W.R. Twisk, PhD; Jos H.M. Dekker, MD;
Peter de Koning, MD; Peter A. Koppe, MD; Gustaaf J. Lankhorst, MD, PhD; Lex M. Bouter, PhD
Background and Purpose—Hemiplegic shoulder pain is not uncommon after stroke. Its origin is still unknown, and
although many different methods of treatment are applied, none have yet been proved to be effective. We sought to study
the efficacy of 3 injections of intra-articular triamcinolone acetonide on pain and arm function in stroke patients with
hemiplegic shoulder pain.
Methods—In a multicenter, randomized, placebo-controlled clinical trial, patients with hemiplegic shoulder pain received
either 3 intra-articular injections of 40 mg triamcinolone acetonide or 1 mL physiological saline solution (placebo).
Primary outcomes were pain measured according to 3 visual analogue scales (score range, 0 to 10), and arm function
was measured by means of the Action Research Arm test and the Fugl-Meyer assessment scale; secondary outcomes
were passive external rotation of the shoulder and general functioning measured according to Barthel Index and the
Rehabilitation Activities Profile.
Results—In the triamcinolone group (n518), the median decrease in pain, 3 weeks after the last injection, was 2.3
(interquartile range, 0.3 to 4.3) versus 0.2 (interquartile range, 20.5 to 2.2) in the placebo group. This result was not
statistically significant. The change in the other outcome measures did not differ significantly between the 2 treatment
groups. Twenty-five patients reported side effects.
Conclusions—In the 37 participants included in this study, triamcinolone injections seemed to decrease hemiplegic
shoulder pain and to accelerate recovery, but this effect was not statistically significant. Therefore, on the basis of the
results of this study, these injections cannot be recommended for the treatment of patients with hemiplegic shoulder pain.
(Stroke. 2000;31:2396-2401.)
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The occurrence of hemiplegic shoulder pain varies from16% to 84% in stroke patients.1–8 These patients remain
hospitalized for a longer period of time, and shoulder pain
interferes with the rehabilitation process.6,8 Many different
methods of treatment are applied for hemiplegic shoulder
pain,2,9,10 and many different preventive measures are also
recommended.2,6,7,11–14
The clinical presentation of hemiplegic shoulder pain mimics that
of the frozen shoulder (adhesive capsulitis). Recently, 2 reviews on
the effectiveness of corticosteroid injections for shoulder disorders
(in nonhemiplegics) have been published. Van der Heijden et al15
found some indications for a positive effect of steroid injections for
shoulder disorders, while Green et al16 concluded that these injec-
tions improve the abduction in patients with rotator cuff tendinitis,
but that no conclusion can be drawn about their effectiveness for
patients with a frozen shoulder. However, in clinical practice,
physiatrists frequently treat patients with hemiplegic shoulder pain
with steroid injections.10 In a small, uncontrolled study, Dekker et
al17 found a positive effect of 3 intra-articular injections with
triamcinolone acetonide (a corticosteroid) in 5 of 9 stroke patients
with hemiplegic shoulder pain. However, the question of whether
these injections are more effective than placebo injections remains
unsolved. Therefore, a randomized clinical trial was conducted to
evaluate the effect on pain and arm function of 3 intra-articular
injections of triamcinolone acetonide versus placebo injections in
patients with hemiplegic shoulder pain after stroke.
Subjects and Methods
Design
In a multicenter, placebo-controlled clinical trial, patients were
randomized into 2 groups on the basis of computerized random
numbers. Four strata were defined: rehabilitation centers versus
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nursing homes and onset of stroke shorter or longer than 6 months
before the trial. For the treatment allocation, numbered sealed
envelopes were used. Patients received either 3 injections with
triamcinolone acetonide (40 mg Kenacort A-40 in 1 mL) or 3
placebo injections (1 mL saline solution). The patients and all other
people involved, except for the injecting physicians, were blinded for
the type of treatment. Although an attempt was also made to blind
the injecting physicians, this was not possible. Therefore, in no case
was an injection given by the physiatrist who was treating the
patient. One week before treatment commenced only pain was
measured, and 1 week later all baseline measurements were per-
formed, followed by randomization and the first injection. The third
measurement took place 1 week after baseline, immediately before
the second injection. Two weeks after the second injection the fourth
measurement took place, immediately before the third injection. The
follow-up measurements took place 3 and 9 weeks after the
third injection.
Subjects
Inclusion criteria were as follows: (1) hemiplegia after stroke,
(2) pain in the hemiplegic shoulder $4.0 (on a scale of 0 to 10) on
at least 1 of 3 visual analogue scales (VAS) during at least 2 weeks,
(3) a limitation of the passive external rotation of the hemiplegic
shoulder of .20° compared with the other (unaffected) side, (4) age
18 to 80 years, and (5) written informed consent. The most important
reasons for exclusion were an injection in the affected shoulder
during the previous 6 months or use of systemic corticosteroids
during the previous 3 months, other obvious explanation for the pain
(eg, fracture, luxation), earlier surgery of the involved shoulder,
severe communication problems (,P50 on the Stichting Afasie
Nederland test),18 or severe cognitive problems (#20 on the Mini-
Mental State Examination).19 Patients were initially recruited from 2
rehabilitation centers, but after 6 months, an insufficient number of
patients had been included. Therefore, patients were recruited from
4 additional rehabilitation centers, the rehabilitation wards of 3
nursing homes, and a stroke patient organization. The research
protocol was approved by the ethics committees of all participating
institutions.
Treatment
The injections were given by experienced physicians via the poste-
rior route.20 After each injection the patients were provided with a
sling for the rest of the day, but no further changes were made in
their normal rehabilitation program.
Measurements
Baseline Measures
In addition to demographic and medical characteristics (type of
stroke, side of lesion in the cerebrum, side of hemiplegia, comor-
bidity), the following prognostic factors were measured at baseline.
The grade of subluxation of the shoulder was rated from an x-ray
film of the affected shoulder in an anteroposterior projection, as
described by Van Langenberghe and Hogan.21 Sensory disorders
were dichotomized: any sensory deviation reported by the patient in
a test involving touching or pin-pricking of the arms, or in a test for
vibration disorders with a tuning fork on the distal end of the radius,
was rated as abnormal. Visual field deficits were tested by means of
the direct confrontation method.22 Neglect was measured according
to a letter cancellation test and a line bisection test and was defined
as the difference between right and left of .2 missed O’s on a letter
cancellation test or ,34 O’s canceled of 40, or a mean deviation of
.17.9 mm for neglect of the left side or .26.1 mm for neglect of
the right side on a line bisection test that consisted of 10 lines of 10
cm. Similar tests are described elsewhere.23,24 Spasticity was as-
sessed during passive motion in the elbow joint and rated according
to the Ashworth scale.25 The presence or absence of a shoulder-hand
syndrome was rated according to the criteria of Tepperman et al.26
Primary Outcome Measures
Pain was measured according to 3 vertical VASs of 10.0 cm each:
pain today, pain during the day in the previous week, and pain during
the night in the previous week.27,28 The bottom of the scale was no
pain at all, and the top was very severe pain. The outcome measure
was calculated as the mean of the pain scores during the day and
during the night in the previous week. The arm function was assessed
by means of the Action Research Arm test,29,30 which consists of 19
items focusing on grasping objects of different shapes and sizes and
gross movements of the arm (score range, 0 to 57). The Fugl-Meyer
assessment scale for the upper extremity and coordination (32 items;
score range, 0 to 66) was used to assess the impairment level of the
arm function.31 In both the Action Research Arm test and the
Fugl-Meyer assessment scale, a higher score indicates a higher
functional level.
Secondary Outcome Measures
The passive range of external rotation of the shoulder was measured
with a fluid-filled goniometer.32 The functional level of the patients
was measured according to the Barthel Index33 (10 items; score
range, 0 to 20) and 4 domains of the Rehabilitation Activities Profile:
communication, mobility, personal care, and occupation.34 The
Rehabilitation Activities Profile score was calculated as the percent-
age of the maximum possible score for each patient. For both the
Barthel Index and the Rehabilitation Activities Profile, a higher score
indicates a lower functional level. After each injection, the injecting
physicians were asked how sure they were that the injection was
intra-articular. All cointerventions and side effects were recorded.
Statistical Analysis
The greatest difference between the 2 treatment groups was expected
to be found between baseline and the first follow-up, which took
place after 3 weeks. Therefore, for every patient the absolute change
in the outcome scores between baseline and the first follow-up
measurement was calculated, so that a positive difference indicated
improvement for the patient. Because of the small number of patients
in both groups and the skewed distribution of the differences
between the 2 groups, a nonparametric test (Mann-Whitney U test)
was used, with the exact method used to calculate the P values. The
level of statistical significance was set at 0.05. Median differences
between the groups and the 95% CIs were calculated.35
Additional analyses were applied to identify specific subgroups in
which the results differed from the overall results. These subgroups
were based on sex, type of lesion, side of hemiplegia, involvement of
the dominant side, time since onset of stroke, time since onset of
hemiplegic shoulder pain, recruitment source, sensory disorders,
visual field deficits, neglect, spasticity, cointerventions, and comor-
bidity. SPPS 9.0 for Windows 95 was used for these analyses.
A DOS version of Spida was used to calculate the Generalized
Estimating Equations (GEE) for repeated measures in an additional
analysis, with the mean pain during the previous week as outcome.
Interaction between the treatment group and time was also studied.
The advantage of GEE is that the data of all 6 measurements are
included. However, with a small number of patients the point
estimator becomes less reliable.
A priori, the minimal clinically important difference (MCID)
between the treatment groups were defined as follows: for pain, the
MCID was a decrease of $30% in the total range of the scale on the
VAS for pain during the previous week; for the Action Research
Arm test, Fugl-Meyer assessment scale, and Rehabilitation Activities
Profile, the MCID was a difference of 10% in the total range of the
scale; for the Barthel Index, the MCID was a difference of $4 points
of 20.33
Results
Figure 1 shows that 37 patients were randomized. Twenty-
seven patients were recruited from 6 rehabilitation centers, 8
from 3 nursing homes, and 2 from a stroke patient organiza-
tion. Two patients in the triamcinolone group did not receive
the third injection but completed the follow-up measure-
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ments. In the placebo group, 2 patients dropped out because
the injections had insufficient effect: 1 after 2 injections and
the other after 3 injections.
Table 1 shows the baseline characteristics of the included
patients. Despite randomization, sex and side of lesion were
not equally distributed over the 2 groups. None of the patients
suffered from a shoulder-hand syndrome. No differences
were found in the use of preventive measures (supportive
sling, lap board) or in the number of patients who received
additional physiotherapy or occupational therapy for their
shoulder. At baseline the groups did not differ with regard to
the outcome variables (Table 2). Because of logistic prob-
lems, the x-ray films, which were taken to evaluate the degree
of subluxation, were of insufficient quantity and quality, and
therefore this variable could not be included.
The course of pain over time is presented in Figure 2. In
none of the measurements did the pain scores differ signifi-
cantly between the groups. The use of GEE also showed no
significant difference between the 2 treatment groups. The
distributions of the other primary outcomes were too skewed
to warrant application of GEE.
Table 3 shows the results of the nonparametric tests for all
outcome measures. No significant or clinically relevant dif-
ferences between the 2 groups were found.
In the subgroups of patients with no sensory disorders, pain
decreased by 3.6 in the triamcinolone group and by 0.3 in the
placebo group (median difference, 2.7; 95% CI, 0.6 to 5.1). In
patients with no visual field deficits, pain decreased by 3.0 in
the triamcinolone group and increased by 0.1 in the placebo
group (median difference, 2.3; 95% CI, 0.3 to 4.4) and in
patients with no neglect pain decreased by 3.3 in the triam-
cinolone group versus 0.5 in the placebo group (median
difference, 2.2; 95% CI, 0.1 to 4.4). In other subgroup
analyses, however, some significant differences with no
biologically plausible explanation were found (data available
from the author on request). For the secondary outcome
measures (passive external rotation of the shoulder, Barthel
Index, Rehabilitation Activities Profile), no significant differ-
ences were found.
The results concerning correct placement of the injections
are presented in Table 4. According to the injecting physi-
cians, 51% of the triamcinolone injections were certainly
intra-articular versus 30% of the placebo injections. This
difference of 21% is statistically significant (95% CI, 3%
to 40%).
After the last measurement, the blinded outcome assessor
guessed the applied treatment correctly in 21 of 35 cases
(60%): 11 of 17 cases (65%) of the placebo group and 10 of
18 cases (56%) of the triamcinolone group.
Twenty-five patients reported 1 or more side effects: 12 of
these patients were treated with triamcinolone injections and
13 with placebo injections. Table 5 presents the reported side
effects. In the patients with diabetes, no disturbances of the
blood glucose level were detected.
Discussion
Before recruitment commenced, it was calculated that at least
35 patients in each group would be needed to obtain sufficient
power to detect a statistically significant and clinically
relevant reduction in pain. A power calculation based on the
available data36 revealed a power of 0.5 for detecting the
predefined minimum clinically relevant difference in pain
improvement. Therefore, the small number of patients in-
Figure 1. Randomization, compliance, and follow-up of
patients.
TABLE 1. Patient Characteristics at Baseline
Triamcinolone
(n518)
Placebo
(n519)
Age, mean (SD), y 60.6 (8.4) 62.5 (10.6)
Sex, F/M 6/12 12/7
Type of lesion, hemorrhage/infarction 4/14 5/14
Side of hemiplegia, right/left 9/9 5/14
Involvement of dominant side 9 7
Time since onset of stroke, ,6 mo/$6 mo 11/7 13/6
Time since onset hemiplegic shoulder pain,
,6 mo/$6 mo
12/6 14/5
Sensory disorder 11 8*
Visual field deficits 3 3
Neglect 7* 7*
No hypertonia (Ashworth 0–1) 7 9
Hypertonia (Ashworth 2–4) 11 10
Cointerventions 10* 14
Comorbidity (diabetes mellitus) 15 (3) 16 (4)
*One case missing.
TABLE 2. Outcome Measures at Baseline
Triamcinolone
(n518)
Placebo
(n519)
Pain previous week (VAS) 5.1 4.0
(4.2 to 6.3) (2.5 to 6.6)
Action Research Arm test 0 0
(0 to 17)* (0 to 31)
Fugl-Meyer 6.5 12
(4 to 44.3) (4 to 49)
Passive external rotation, ° 20 10
(21.3 to 36.3) (0 to 30)
Barthel Index 4 6
(3 to 10.3) (2 to 9)
Rehabilitation Activities Profile, % of 52.1 54.2
maximum possible score (40.1 to 64.6) (45.8 to 60.8)
Values are median (interquartile range).
*One case missing.
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cluded in the study may be the main reason why the effect of
the intervention on pain was not statistically significant. The
recruitment of patients from various sources may have diluted
the results in 2 different ways. First, recruitment of patients
from various sources probably introduced additional factors
that could have interfered with the experimental treatment but
could not be controlled for. Second, the increase in the
number of recruitment sources also increased the number of
injecting physicians (in total, 16 different physicians were
involved).
The effect of intra-articular injections was studied, and the
reported number of intra-articular injections given differed in
the 2 groups (Table 4). Although it has been reported that
intra-articular corticosteroid injections are more effective
than non–intra-articular injections,37 the clinical importance
of this finding is unclear.38 Therefore, it can be assumed that
this difference between the groups did not influence the
outcomes of the study.
To measure pain, 3 VASs were used: pain today, pain
during the day in the previous week, and pain during the night
in the previous week. Patients were included if they rated
their pain $4.0 on $1 of these 3 scales at the first and second
measurements. The effect of the intervention was based on
the mean pain score during the previous week. There was no
difference in effect between the 13 patients who rated their
mean pain during last week ,4.0 and the 24 who rated their
pain $4.0. Although the VAS is a generally accepted and
validated instrument to measure pain and other subjective
feelings,27,39–41 several researchers have recently reported
problems when applying a VAS to stroke patients.42–44 These
findings were confirmed in the present study: several patients
had serious problems with understanding the VAS and how to
complete it. However, an additional question about pain,
which could easily be answered by the patients, revealed
similar results (data not shown).
Pain in the shoulder and limitation of the passive move-
ments of the shoulder, especially of the external rotation, are
Figure 2. Median pain scores during the study
period; the injections were given at weeks 0, 1,
and 3.
TABLE 3. Median Improvement 3 Weeks After Last Injection
Triamcinolone*
(n518)
Placebo*
(n517)
Mann-Whitney
P
Median of Differences†
(95% CI)
Pain (VAS) 2.3 0.2 0.06 1.9
(0.3 to 4.3) (20.5 to 2.2) (20.1 to 3.7)
Action Research Arm test 0‡ 0 0.17 0
(0 to 1.0) (0 to 3.8) (23.0 to 0)
Fugl-Meyer 3.5 1.0 0.41 2.0
(0 to 8.0) (0 to 3.8) (21.0 to 5.0)
Passive external rotation, ° 2.5 0 0.71 4.3
(211.3 to 21.3) (210.0 to 10.0) (214.3 to 25.0)
Barthel Index 1.5 1.0 0.85 0
(0 to 3.3) (25.0 to 4.0) (22.0 to 2.0)
Rehabilitation Activities Profile, % 15.9 6.3 0.17 7.5
of maximum possible score (2.1 to 21.4) (26.3 to 17.1) (23.0 to 15.3)
*Positive numbers indicate improvement of the patient.
†Positive numbers indicate a greater effect in triamcinolone group than in placebo group.
‡One case missing.
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the clinical signs on which the diagnosis of capsulitis of the
shoulder is based.45 However, pain and a limitation of the
external rotation of the shoulder are sometimes attributed to
spasticity of the shoulder muscles.3,6,7,13 When spasticity is
the main cause of pain, it is unlikely that triamcinolone will
have a significant effect. It is difficult to distinguish between
pain in the limited hemiplegic shoulder based on capsulitis
alone, pain based on spasticity alone, or a combination of
these.
Recurrent injuries allegedly maintain a capsulitis.46,47 Pa-
tients with sensory disorders, visual field deficits, or neglect
have a higher risk of recurrent injuries of the shoulder,
possibly resulting in capsulitis, and triamcinolone injections
will not resolve this problem. The subgroup analyses in this
study seem to confirm this hypothesis, but the number of
patients in these subgroups was very small, and therefore no
firm conclusions can be drawn.
The absolute change scores were used as an outcome
measure. Statisticians disagree on whether it is preferable to
use relative change scores48 or absolute change scores.49
However, there is agreement that an absolute outcome with-
out correction for baseline differences would not be appro-
priate. In this study analysis was performed with both
absolute and relative change scores, and similar results were
found. Because absolute change scores are more easily
interpreted, these are presented.
It was very surprising that it was so difficult to find patients
with hemiplegic shoulder pain, which suggests that the
occurrence rates reported in the literature should be reexam-
ined. In recent years much emphasis has been placed on the
prevention of hemiplegic shoulder pain in the Netherlands,
and it seems that the problem is becoming less common.
However, if a patient develops hemiplegic shoulder pain, the
question of the manner of treatment remains unanswered. No
significant effect of triamcinolone injections was found, and
side effects were frequently reported (although most of these
were not serious). A new and larger randomized trial should
be executed to draw definite conclusions about the efficacy of
triamcinolone injections and to identify subgroups of patients
for whom these injections are effective. However, on the
basis of the results of this study, intra-articular triamcinolone
injections cannot be recommended for the treatment of
hemiplegic shoulder pain.
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